References
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA: Canc J Clinician 2012, 62(1):10–29.
Kokko LL, Hurme S, Maula SM, Alanen K, Grenman R, Kinnunen I, Ventela S: Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous cell carcinoma. Oral Oncol 2011, 47(6):510–516.
Institute NC. Cancer Stat Facts: Larynx Cancer Surveillance, Epidemiology, and Results (SEER) database. 2016.
Wolf GT, Fisher SG, Hong WK, et al. Induction chemotherapy plus radiation comparedd with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324(24):1685–90.
Ries LA, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER cancer statistics review, 1975-2003. Bethesda, MD: National Cancer Institute; 2006.
Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol. 2001;19:4029-36.
Karatzanis AD, Psychogios G, Zenk J, Waldfahrer F, Hornung J, Velegrakis GA, et al. Comparison among different available surgical approaches in T1 glottic cancer. Laryngoscope. 2009; 119:1704-8.
Silver CE, Beitler JJ, Shaha AR, Rinaldo A, Ferlito A. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol. 2009;266: 1333-52.
Yoo J, Lacchetti C, Hammond JA, Gilbert RW; Head and Neck Cancer Disease Site Group. Role of endolaryngeal surgery (with or without laser) versus radiotherapy in the managementt of early (T1) glottic cancer: a systematic review. Head Neck. 2014;36:1807-19.
Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer. 2004;100:1786-92.8.
Abdurehim Y, Hua Z, Yasin Y, Xukurhan A, Imam I, Yuqin F.Transoral laser surgery versus radiotherapy: systematic review and meta-analysis for treatment options of T1a glottic cancer. Head Neck. 2012;34:23-33.
Wiernik G, Millard PR, Haybittle JL. The predictive value of histological classification into degrees of differentiation of squamous cell carcinoma of the larynx and hypopharynx compared with the survival of patients. Histopathology 1991; 19:411-417.
Westerbeek HA, Mooi WJ, Hilgers FJ, Baris G, Begg AJ, Balm AJ. Ploidy status and the response of T1 glottic carcinoma to radiotherapy. Clin Otolaryngol 1993: 18:98-101.
Gallo O, Libonati GA, Gallina E, Fini-Storchi O, Giannini A, Urso C, Bondi R. Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 1991, 117:1007-1010.
Lobo NA, Shimono Y, Qian D, Clarke MF: The biology of cancer stem cells. Ann Rev Dev Biol 2007, 23:675–699.
Bomken S, Fiser K, Heidenreich O, Vormoor J: Understanding the cancer stem cell. Br J Canc 2010, 103(4):439–445.
Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF: Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Canc Res: Offic J Am Assoc Canc Res 2008, 14(13):4085–4095.
Yu CC, Chang YC: Enhancement of cancer stem-like and epithelial-mesenchymall transdifferentiation property in oral epithelial cells with long-term nicotine exposure: reversal by targeting SNAIL. Toxicol Appl Pharmacol 2013, 266(3):459–469.
Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, Lo JF: CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PloS One 2011, 6(11):e28053.
Trapasso S, Allegra E: Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biol: Targets Ther 2012, 6:379–383.
Joshua B, Kaplan MJ, Doweck I, Pai R, Weissman IL, Prince ME, Ailles LE: Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck 2012, 34(1):42–49.
Chikamatsu K, Takahashi G, Sakakura K, Ferrone S, Masuyama K: Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head & neck 2011, 33(2):208–215.
Amin M, Edge S, Greene F, et al. AJCC cancer staging manual. Eighth ed. New York: Springer; 2017.
Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, Kaufmann AM, et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS ONE. 2011;6(1):e16466.
Greco N, Schott T, Mu X, Rothenberg A, Voigt C, McGough RL III, et al. ALDH activity correlates with metastatic potential in primary sarcomas of bone. J Cancer Ther. 2014;5(4):331–8.
Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385(3):307–13.
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8.
Al-Assar O, Muschel RJ, Mantoni TS, McKenna WG, Brunner TB. Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys. 2009;75(4):1216–25.
Zhou C, Sun B. The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: a meta-analysis. Oral Oncol. 2014;50(12):1144–8.
Lopez-Gonzalez A, Salas C, Provencio M, Cordoba M, Gamallo C. Aldehyde dehydrogenases in early stage lung cancer: nuclear expression. Clin Transl Oncol. 2014;16(10):931–4.